Scholar Rock (NASDAQ:SRRK) Stock Price Up 5.8% - What's Next?

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report)'s stock price shot up 5.8% on Tuesday . The company traded as high as $31.06 and last traded at $30.61. 107,710 shares were traded during mid-day trading, a decline of 91% from the average session volume of 1,217,614 shares. The stock had previously closed at $28.93.

Analysts Set New Price Targets

Separately, Wedbush reiterated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Price Performance

The firm has a market cap of $2.91 billion, a PE ratio of -13.07 and a beta of 0.56. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $33.26 and a two-hundred day moving average price of $35.27.

Insiders Place Their Bets

In other Scholar Rock news, CEO Jay T. Backstrom sold 18,372 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $676,640.76. Following the sale, the chief executive officer now owns 311,991 shares in the company, valued at approximately $11,490,628.53. The trade was a 5.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. This represents a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 250,231 shares of company stock valued at $9,056,086. Insiders own 19.20% of the company's stock.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently bought and sold shares of the company. Barclays PLC boosted its holdings in shares of Scholar Rock by 103.4% in the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after acquiring an additional 84,118 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Scholar Rock by 8.5% in the third quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after purchasing an additional 120,489 shares during the last quarter. Vanguard Group Inc. grew its position in Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock worth $205,013,000 after purchasing an additional 708,817 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Scholar Rock during the 4th quarter valued at about $274,000. Finally, Rhumbline Advisers lifted its holdings in shares of Scholar Rock by 13.2% in the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock valued at $4,895,000 after buying an additional 13,247 shares during the period. Hedge funds and other institutional investors own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.